{"id":"lidoflazine","rwe":[{"pmid":"39796172","year":"2025","title":"Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"38956669","year":"2024","title":"Leveraging a neutrophil-derived PCD signature to predict and stratify patients with acute myocardial infarction: from AI prediction to biological interpretation.","finding":"","journal":"Journal of translational medicine","studyType":"Clinical Study"},{"pmid":"36333468","year":"2022","title":"NRBF2-mediated autophagy contributes to metabolite replenishment and radioresistance in glioblastoma.","finding":"","journal":"Experimental & molecular medicine","studyType":"Clinical Study"},{"pmid":"30486354","year":"2018","title":"Cardiovascular Profile of Xanthone-Based 1,4 Dihydropyridines Bearing a Lidoflazine Pharmacophore Fragment.","finding":"","journal":"Molecules (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"30364900","year":"2018","title":"Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.","finding":"","journal":"Therapeutic advances in drug safety","studyType":"Clinical Study"}],"tags":[{"label":"lidoflazine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Potassium voltage-gated channel subfamily H member 2","category":"target"},{"label":"KCNH2","category":"gene"},{"label":"SLC29A1","category":"gene"},{"label":"C08EX01","category":"atc"},{"label":"Active","category":"status"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"},{"label":"Vasodilator Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"corflazine","offLabel":[],"synonyms":["lidoflazine","corflazine","lidoflazin","lidoflazinum","ordiflazine"],"timeline":[],"approvals":[],"brandName":"Corflazine","ecosystem":[],"mechanism":{"target":"Equilibrative nucleoside transporter 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel alpha subunits; brain (Types I, II, III)","targets":[{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"SLC29A1","source":"DrugCentral","target":"Equilibrative nucleoside transporter 1","protein":"Equilibrative nucleoside transporter 1"}],"modality":"Small Molecule","drugClass":"lidoflazine","explanation":"Think of your body's cells like tiny electrical circuits. Potassium channels help control the flow of electrical signals within these circuits. By blocking these channels, Corflazine helps to slow down the electrical activity of cells, which can be beneficial in certain medical conditions.","oneSentence":"Corflazine works by blocking potassium channels in the body, which helps to regulate the electrical activity of cells.","technicalDetail":"Corflazine targets the Kv11.1 potassium channel, specifically the KCNH2 gene product, to modulate the flow of potassium ions across the cell membrane, thereby influencing the resting membrane potential and action potential duration."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1580","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LIDOFLAZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:07:06.495176","biosimilars":[],"competitors":[{"drugName":"abemaciclib","drugSlug":"abemaciclib","fdaApproval":"2017-09-28","patentExpiry":"Sep 28, 2031","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"alosetron","drugSlug":"alosetron","fdaApproval":"2000-02-09","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amiodarone","drugSlug":"amiodarone","fdaApproval":"1985-12-24","patentExpiry":"Mar 13, 2029","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amodiaquine","drugSlug":"amodiaquine","fdaApproval":"","patentStatus":"Unknown","relationship":"same-target"},{"drugName":"aripiprazole","drugSlug":"aripiprazole","fdaApproval":"2002-11-15","patentExpiry":"Sep 24, 2033","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"arsenic trioxide","drugSlug":"arsenic-trioxide","fdaApproval":"2000-09-25","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"asciminib","drugSlug":"asciminib","fdaApproval":"2021-10-29","patentExpiry":"Oct 29, 2035","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"astemizole","drugSlug":"astemizole","fdaApproval":"1988-12-31","relationship":"same-target"},{"drugName":"atomoxetine","drugSlug":"atomoxetine","fdaApproval":"2002-11-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lidoflazine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"abemaciclib","brandName":"abemaciclib","genericName":"abemaciclib","approvalYear":"2017","relationship":"same-target"},{"drugId":"alosetron","brandName":"alosetron","genericName":"alosetron","approvalYear":"2000","relationship":"same-target"},{"drugId":"amiodarone","brandName":"amiodarone","genericName":"amiodarone","approvalYear":"1985","relationship":"same-target"},{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amodiaquine","brandName":"amodiaquine","genericName":"amodiaquine","approvalYear":"","relationship":"same-target"},{"drugId":"aripiprazole","brandName":"aripiprazole","genericName":"aripiprazole","approvalYear":"2002","relationship":"same-target"},{"drugId":"arsenic-trioxide","brandName":"arsenic trioxide","genericName":"arsenic trioxide","approvalYear":"2000","relationship":"same-target"},{"drugId":"asciminib","brandName":"asciminib","genericName":"asciminib","approvalYear":"2021","relationship":"same-target"},{"drugId":"astemizole","brandName":"astemizole","genericName":"astemizole","approvalYear":"1988","relationship":"same-target"},{"drugId":"atomoxetine","brandName":"atomoxetine","genericName":"atomoxetine","approvalYear":"2002","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NUI":"N0000167118","UNII":"J4ZHN3HBTE","CHEBI":"CHEBI:93095","INN_ID":"1925","RXNORM":"6390","UMLSCUI":"C0023665","ChEMBL_ID":"CHEMBL92870","KEGG_DRUG":"D04733","DRUGBANK_ID":"DB13766","PUBCHEM_CID":"3926","SNOMEDCT_US":"319206000","MESH_DESCRIPTOR_UI":"D008013"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":278,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"C08EX01","allCodes":["C08EX01"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Jan 1","pmid":"39796172","title":"Repurposing FDA-Approved Drugs for Eumycetoma Treatment: Homology Modeling and Computational Screening of CYP51 Inhibitors.","journal":"International journal of molecular sciences"},{"date":"2024 Jul 2","pmid":"38956669","title":"Leveraging a neutrophil-derived PCD signature to predict and stratify patients with acute myocardial infarction: from AI prediction to biological interpretation.","journal":"Journal of translational medicine"},{"date":"2022 Nov","pmid":"36333468","title":"NRBF2-mediated autophagy contributes to metabolite replenishment and radioresistance in glioblastoma.","journal":"Experimental & molecular medicine"},{"date":"2018 Nov 27","pmid":"30486354","title":"Cardiovascular Profile of Xanthone-Based 1,4 Dihydropyridines Bearing a Lidoflazine Pharmacophore Fragment.","journal":"Molecules (Basel, Switzerland)"},{"date":"2018 Aug","pmid":"30364900","title":"Withdrawal of prenylamine: perspectives on pharmacological, clinical and regulatory outcomes following the first QT-related casualty.","journal":"Therapeutic advances in drug safety"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Corflazine, also known as LIDOFLAZINE, is a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It is classified as a lidoflazine drug and works by modulating ion channels to affect cellular excitability. However, due to the lack of available information, its commercial status, approved indications, half-life, bioavailability, and generic manufacturers are unknown. As a result, its FDA approval status and off-patent status also remain unclear. Further research is necessary to fully understand the properties and applications of Corflazine.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}